It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes stillbirths compared with other Short Course Regimen (very low certainty).
It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes mother to Child Transmission of HIV at 1 Month compared with other Short Course Regimen (very low certainty).
It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes mother to Child Transmission of HIV at 12 Months compared with other Short Course Regimen (very low certainty).
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in low Birth Weight compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… led to higher severe pain for > 1 week compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.
Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… showed no clear difference in experienced the operation negatively compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.
Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… led to lower no improvement of facial appearance (3 weeks) compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.
Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… showed no clear difference in prosthetic failure compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.
Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… led to higher major complications compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.
Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… showed no clear difference in implant failure compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).